Edition:
India

Aurinia Pharmaceuticals Inc (AUP.TO)

AUP.TO on Toronto Stock Exchange

8.50CAD
16 Jul 2019
Change (% chg)

-- (--)
Prev Close
$8.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
46,610
52-wk High
$10.47
52-wk Low
$6.61

Latest Key Developments (Source: Significant Developments)

Aurinia Pharmaceuticals Inc Qtrly Loss Per Share $0.14
Wednesday, 15 May 2019 

May 14 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS.AURINIA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.14.AURINIA PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS OF $144.3 MILLION AS OF MARCH 31, 2019.  Full Article

Iljin SNT Co Says Now "Seriously Considering" Whether To Nominate New Directors To Aurinia's Board
Tuesday, 9 Apr 2019 

April 8 (Reuters) - Aurinia Pharmaceuticals Inc ::ILJIN SNT CO LTD SAYS NOW "SERIOUSLY CONSIDERING" WHETHER TO NOMINATE NEW DIRECTORS TO AURINIA'S BOARD.ILJIN SNT SAYS CONSIDERING WHETHER TO BUY MORE SECURITIES OF AURINIA PHARMACEUTICALS IN OPEN MARKET DEALS, PRIVATE TRANSACTIONS/OTHERWISE.ILJIN SNT SAYS CHIN KYU HUH REPORTS 14.5 PERCENT STAKE IN AURINIA PHARMACEUTICALS AS OF FEB 14 - SEC FILING.  Full Article

Aurinia Qtrly Loss Per Share $0.17
Wednesday, 20 Mar 2019 

March 19 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.AURINIA PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS OF $125.9 MILLION AS OF DECEMBER 31, 2018..AURINIA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.17.  Full Article

Aurinia Pharmaceuticals Richard Glickman, Chairman And Chief Executive Officer, To Retire
Friday, 9 Nov 2018 

Nov 8 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA REPORTS THIRD QUARTER FINANCIAL RESULTS, CLINICAL HIGHLIGHTS AND CORPORATE DEVELOPMENT.AURINIA PHARMACEUTICALS INC - RICHARD M. GLICKMAN, COMPANY'S CHAIRMAN AND CHIEF EXECUTIVE OFFICER, INTENDS TO RETIRE.AURINIA PHARMACEUTICALS - GLICKMAN TO RETIRE AS CEO ONCE A REPLACEMENT IS IDENTIFIED AND APPOINTED.AURINIA PHARMACEUTICALS INC - AT SEPTEMBER 30, 2018, WE HAD CASH, CASH EQUIVALENTS AND SHORT TERM INVESTMENTS OF $138.9 MILLION.AURINIA PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.21.  Full Article

Aurinia Completes Enrollment Of Aurora, Its Phase 3 Clinical Trial For The Treatment Of Lupus Nephritis
Wednesday, 26 Sep 2018 

Sept 25 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA COMPLETES ENROLLMENT OF AURORA, ITS PHASE 3 CLINICAL TRIAL FOR THE TREATMENT OF LUPUS NEPHRITIS.AURINIA COMPLETES ENROLLMENT OF AURORA, ITS PHASE 3 CLINICAL TRIAL FOR THE TREATMENT OF LUPUS NEPHRITIS.AURINIA PHARMACEUTICALS INC - COMPANY ANTICIPATES PRIMARY DATA ANALYSIS IN Q4 2019.  Full Article

Aurinia reports Q3 loss per share $0.16
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Aurinia Pharmaceuticals Inc :Aurinia reports third quarter 2017 financial results and provides operational highlights.Aurinia Pharmaceuticals Inc - ‍Aurora phase III trial in lupus nephritis on track​.Q3 loss per share $0.16.Aurinia Pharmaceuticals - Believe​ co have sufficient financial resources to fund LN program,conduct work on new indications & fund operations into 2020.  Full Article

Robert Duggan reports 5.9 pct stake in Aurinia Pharmaceuticals - SEC filing‍​
Tuesday, 24 Oct 2017 

Oct 23 (Reuters) - Aurinia Pharmaceuticals Inc : :Robert Duggan reports 5.9 percent stake in Aurinia Pharmaceuticals Inc as on October 19, 2017 - SEC filing‍​.Robert Duggan had previously reported 7.2 percent stake in Aurinia Pharmaceuticals Inc as on April 21, 2017.  Full Article

Aurinia Pharmaceuticals plans to expand voclosoprin renal franchise
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Aurinia Pharmaceuticals Inc :Aurinia Pharmaceuticals Inc - ‍ plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease​.Aurinia Pharmaceuticals - ‍ plans to evaluate proprietary nanomicellar voclosporin ophthalmic solution for treatment of keratoconjunctivitis sicca/ DES.Aurinia Pharmaceuticals - ‍a phase II proof of concept clinical trial for voclosporin in FSGS and MCD patients will be initiated in first half of 2018​.  Full Article